Two cases of opportunistic parasite infections in patients receiving alemtuzumab by Desoubeaux, Guillaume et al.
HAL Id: hal-02439688
https://hal.archives-ouvertes.fr/hal-02439688
Submitted on 14 Jan 2020
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Two cases of opportunistic parasite infections in patients
receiving alemtuzumab
Guillaume Desoubeaux, Charline Caumont, Christophe Passot, Caroline
Dartigeas, Éric Bailly, Jacques Chandenier, Thanh Haï Duong
To cite this version:
Guillaume Desoubeaux, Charline Caumont, Christophe Passot, Caroline Dartigeas, Éric Bailly, et
al.. Two cases of opportunistic parasite infections in patients receiving alemtuzumab. Journal of
Clinical Pathology, BMJ Publishing Group, 2011, 65 (1), pp.92-95. ￿10.1136/jclinpath-2011-200403￿.
￿hal-02439688￿
HAL Id: hal-02439688
https://hal.archives-ouvertes.fr/hal-02439688
Submitted on 14 Jan 2020
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Two cases of opportunistic parasite infections in patients
receiving alemtuzumab
Guillaume Desoubeaux, Charline Caumont, Christophe Passot, Caroline
Dartigeas, Éric Bailly, Jacques Chandenier, Thanh Duong
To cite this version:
Guillaume Desoubeaux, Charline Caumont, Christophe Passot, Caroline Dartigeas, Éric Bailly, et al..
Two cases of opportunistic parasite infections in patients receiving alemtuzumab. Journal of Clinical
Pathology, BMJ Publishing Group, 2011, ￿10.1136/jclinpath-2011-200403￿. ￿hal-02439688￿
Two cases of opportunistic parasite infections in
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ABSTRACT
Two cases are reported of rare digestive opportunistic
parasites in patients being treated with alemtuzumab for
lymphoid haematological malignancies. In both patients,
classical biological examinations were insufficient to
reach the diagnosis. Only specific parasitological
techniques enabled diagnoses of cryptosporidiosis and
microsporidiosis, respectively. In both cases, cellular
immune reconstitution was sufficient to eradicate these
opportunistic infections. In this context, parasitological
diagnosis is often underestimated by medical
practitioners, so immunologists and oncohaematologists
need to be aware of this kind of opportunistic pathogen.
Numerous digestive complicationsdinfectious or
non-infectiousdmay arise during treatment with
alemtuzumab (Campath; Genzyme, USA).1e3
Among these, two rare parasites which are well-
known in departments of infectious diseases,
particularly during the HIV/AIDS outbreak, may be
suspected. Case reports of two patients treated
with alemtuzumab in whom opportunistic para-
sitic infections developed are described.
CASE 1
A 75-year-old woman was monitored for stage C
chronic lymphocytic leukaemia (CLL) initially
diagnosed in 2005. She was started on a fourth
course of treatment with alemtuzumab at the
end of March 2011 and pancytopenia with
lymphocyte depletion (measured values
0e0.6103109/l) was noticed on regular complete
blood counts. In May 2011 she presented with
a 2-week history of diarrhoea with at least three
watery stools per day. She had not undertaken any
foreign travel. All the routine tests were negative
(bacterial culture, virus research by immunological
or molecular methods, standard stool analysis for
parasites and anatomopathological examinations
of bowel biopsies). As the stools were very liquid,
the parasitology laboratory decided to perform
further investigations. The temporary wet mount
and two concentration techniques (Bailenger ’s
sedimentation and Kato-Katz’s techniques) were
negative, but ZiehleNeelsen staining revealed the
presence of Cryptosporidium oocysts on smears of
methanol-ﬁxed faeces (ﬁgure 1) and C meleagridis
was identiﬁed upon 18S rRNA gene sequencing.
Treatment of symptoms and an increase in
lymphocyte count after stopping alemtuzumab
treatment resulted in a favourable outcome
within a few weeks.
CASE 2
A 77-year-old man presented with uncontrolled
CLL after ﬁve sessions of chemotherapy. Alemtu-
zumab treatment was started in January 2011.
Complete blood counts showed lymphocyte counts
of 0.3e0.83109/l from January to June 2011. Since
starting treatment with alemtuzumab, recurrent
aqueous diarrhoea had occurred. The patient had
not undertaken any foreign travel. Routine biolog-
ical tests were negative. The only test with a posi-
tive result was Enterocytozoon bieneusi real-time PCR
with internal positive control performed on a stool
sample (LightCycler 480, Roche Diagnostics,
France) (ﬁgure 2). The microsporidial gene fragment
targeted was the SSU rDNA. Designed Eb1
(59-CGACAGCCTGTGTGTGAGAATAC) and Eb5
(59-CAACGAATGACTTGACCCTGGTAA) were
used as primers and EbS2 (6FAM TGCTTAATT-
TAACTCAACGCGGGAAAA TAMRA) was chosen
as the ﬂuorescent TaqMan probe. Parasitological
conﬁrmation was made with Weber ’s Trichrome
blue stain (ﬁgure 3) and van Gool’s Uvitex 2B
ﬂuorescent brightener (ﬁgure 4) which enabled
detection of microsporidia. As the lymphocyte
count reached the value of 13109/l, the diarrhoea
gradually decreased without speciﬁc treatment.
Neither a whole microsporidial microorganism nor
DNAwas detected in later stool samples after total
cellular immune reconstitution obtained within
3 months.
DISCUSSION
Microorganisms of the genuses Enterocytozoon
and Cryptosporidium are ubiquitous unicellular
Figure 1 Cryptosporidium oocysts stained with Ziehle-
Neelsen acid fast stain (x1000 magnification). The arrow
shows the oocyst stained sharply on a blue-green
background and measuring 5 m. When sporulation occurs,
sporozoites are sometimes clearly visible inside the oocyst.
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eukaryotes whose epidemiology is often linked to the quality of
the water source.4 5 The former belongs to the Microsporidia
group and the latter are coccidia of the Apicomplexa phylum.
Until the middle of the 1990s, microsporidiosis and cryptospo-
ridiosis had been described during episodes of diarrhoea primarily
in HIV-positive persons with AIDS. Since the advent of the
highly active antiretroviral therapies in 1996, such infections
have become rare in treated persons. At present, few cases are
diagnosed in non-HIV subjects, particularly those undergoing
solid organ transplantation/bone marrow graft or those with
leukaemia.6e9 Although the number of cases remains small,
these opportunistic parasites can be highly pathogenic, espe-
cially when the number of CD4 T lymphocytes is <0.23109/l
(note also that immunocompetent subjects may be sporadically
affected by cryptosporidiosis although the pathogenesis is
appreciably different from in immunocompromised patients). As
soon as it is suspected, the diagnosis of cryptosporidiosis is easy
and almost all laboratories should be able to perform correct
staining for Cryptosporidium. In contrast, very few laboratories
can provide a reliable microscopic diagnosis of microsporidiosis.
For the last 20 years the use of monoclonal antibodies has
provided a signiﬁcant improvement in the medical management
of cancer and autoimmune diseases. Alemtuzumab is a human-
ised monoclonal antibody derived from rat. This recombinant
IgG1K targets CD52, a 21e28 kDa surface glycoprotein seen
particularly on mature lymphocytic cells. It is thought to work
via the activation of antibody-dependent cell-mediated cyto-
toxicity10 and/or complement cytotoxicity.11 This drug is indi-
cated in the treatment of relapsing or complicated CLL12 and in
some kinds of non-Hodgkin’s lymphoma. Alemtuzumab is also
Figure 2 Amplification curves of Enterocytozoon bieneusi TaqMan real-time PCR processes at (A) diagnosis and (B) after immune recovery. Each
sample was analysed in duplicate, simultaneously with a positive control. Control DNA was detected with an average Ct of 26 cycles. At the time of
diagnosis, Ct in patient 2 was considered positive at 28 and 30 amplification cycles. As the white blood cell count reached the rate of 1310
9/l
lymphocytes, no microsporidial DNA was further detected.
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sometimes used in some conditioning regimens for bone marrow
graft13 or solid organ transplantation.14 It has also recently been
investigated in a phase II clinical trial in the treatment of
relapsing-remitting multiple sclerosis.15 One of the major
known potential adverse events of alemtuzumab is the increased
risk for onset of opportunistic infections due to intense
lymphocyte depletion associated with profound cellular
immune dysfunction.16e18 No correlation exists between the
cumulative dose of alemtuzumab and the length or severity of
immunodepletion. Many reactivations with herpes or hepatitis
viruses have been reported, especially shortly after the T cell
nadir. For instance, cytomegalovirus reactivation is described in
10e25% of patients receiving alemtuzumab after about
4e6 weeks of treatment.19 20 A few bacterial,2 fungal21 or even
parasitic infections22 have also been reported.1 3 23 This potential
risk therefore requires investigation of the viral serological status
and bacterial colonisation index. In this context, prophylaxis
against various infectious agents should be given until immune
reconstitution.18 24e26
In contrast, infrequent digestive complications due to unicel-
lular pathogens such as microsporidia or cryptosporidia are less
well-known and are often misdiagnosed during treatment with
alemtuzumab. To our knowledge, very few cases of micro-
sporidiosis have been reported in patients treated with alemtu-
zumab.27 No report has been found of cryptosporidiosis caused
by this monoclonal antibody.23 In this context, the risk of such
rare opportunistic parasites is not well known so it is not
sought. However, it appears to be theoretically realistic, even if
there has been no travel in tropical countries. Usually, when
bowel symptoms are observed, digestive graft-versus-host
disease, drug toxicity or bacterial/viral infections are suspected.
As in our case reports, a diagnosis of digestive parasitic infections
usually involves excluding other illnesses. According to the
Crypto-ANOFEL French network recommendations, speciﬁc
parasitological techniques should be performed in cases of liquid
diarrhoea occurring during immunodepletion. For these two
patients, the laboratory used ZiehleNeelsen staining for cryp-
tosporidia and Weber staining for microsporidia detection
followed by conﬁrmation with ﬂuorescence.28 In our laboratory,
molecular methods, which are more sensitive, are recommended
for easier screening of small pathogens such as microsporidia
E bieneusi and are therefore used automatically ﬁrst on every
liquid stool. This method is now standardised, validated and can
also be performed with many real-time machines (Roche
(France), Applied Biosystems).
These cases strengthen the need to consider such environ-
mental eukaryotes as potential pathogens in immunocompro-
mised subjects, including unusual patients from oncohaematology
treated with monoclonal antibodies such as alemtuzumab.
A knowledge of the broad panel of potential infectious agents
enables a better approach for clinicians.23 A delay in the time to
diagnosis can impact on the success of the medical care. A few
antiparasitic treatments have been used with interesting but
controversial successes (eg, nitazoxanide for cryptosporidia,
fumagillin for Enterocytozoon spp. microsporidia).29 30
CONCLUSION
Our ﬁndings suggest that patients treated with alemtuzumab
must be considered a new group of patients with increased
susceptibility to this kind of microorganism, even if they have
not travelled abroad. They should be monitored closely, with an
emphasis on researching opportunistic infectionsdincluding
parasitological infectionsdespecially around the fourth week of
treatment when the lymphocyte number is lowest.
Acknowledgements The authors thank all the personnel in the Parasitology and
Haematology laboratories for their collaboration.
Competing interests None.
Patient consent Obtained.
Contributors Study concept and design: GD, JC. Acquisition of data: GD, CC, CD, JC.
Analysis and interpretation of data: GD, CC, ?Duong, JC. Drafting of the manuscript:
Figure 3 The arrows show two microsporidia spores stained with
Weber’s Trichrome blue stain (x1000 magnification). The parasitic
structures of small size (approximately 1-2 m) are dark in contrast to the
pale background. Mature spores contain a clearly visible vacuole.
Figure 4 Microsporidia spores stained with Uvitex 2B fluorescence
stain (31250 magnification). Once suspected, a confirmatory test is
needed to establish the presence of a microsporidial spore. Enter-
ocytozoon bieneusi spores are seen quite easily with a fluorescent
brightening agent. This latter product fits in the chitinous cell wall of this
kind of microsporidia. Note that the edge of the vacuole appears like
a stick inside the parasitic structure.
Take-home message
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parasits should be suspected as digestive symptoms have began,
especially when they last a few weeks, in spite of antibiotics.
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